Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Piramal Pharma Limited ( (IN:PPLPHARMA) ) has provided an update.
Piramal Pharma Limited reported a 3% year-on-year decline in consolidated revenue from operations to ₹2,140 crore for Q3 FY26 and a 4% drop to ₹6,117 crore for the nine months ended December 31, 2025, with EBITDA down 32% in the quarter and 36% over nine months, and net losses deepening due to lower volumes and exceptional items. Management attributed the muted performance mainly to inventory destocking by a major CDMO customer, slower early-stage order inflows amid uneven US biopharma funding, and regulatory delays affecting inhalation anesthesia exports, but highlighted improving trends since October 2025, including a pickup in RFPs, better funding conditions, and increased US healthcare M&A, alongside ongoing US$90 million growth capex in Lexington and Riverview, expansion of CHG in ex-US markets including the acquisition of Kenalog, and continued outperformance of its consumer business, with expectations that the historically strong fourth quarter will again support results.
More about Piramal Pharma Limited
Piramal Pharma Limited is a leading global pharmaceutical, health and wellness company, operating across contract development and manufacturing (CDMO), complex hospital generics (CHG) and the consumer healthcare (PCH) segments. The company focuses on serving biopharma clients worldwide, supplying specialized hospital formulations, and marketing over-the-counter consumer brands in key markets, with ongoing investments to expand capacity and product offerings, particularly in the US and ex-US markets.
Average Trading Volume: 222,676
Technical Sentiment Signal: Sell
Current Market Cap: 201.2B INR
For an in-depth examination of PPLPHARMA stock, go to TipRanks’ Overview page.